Phosphatidylinositol 4,5-bisphosphate [PtdIns(4,5)P # ] plays a complex role in generating intracellular signalling molecules, and also in regulating actin-binding proteins, vesicular trafficking and vacuolar fusion. Four inositol polyphosphate 5-phosphatases (hereafter called 5-phosphatases) have been identified in Saccharomyces cere isiae : Inp51p, Inp52p, Inp53p and Inp54p. Each enzyme contains a 5-phosphatase domain which hydrolyses PtdIns(4,5)P # , forming PtdIns4P, while Inp52p and Inp53p also express a polyphosphoinositide phosphatase domain within the Sac1-like domain. Disruption of any two yeast 5-phosphatases containing a Sac1-like domain results in abnormalities in actin polymerization, plasma membrane, vacuolar morphology and bud-site selection. Triple null mutant 5-phosphatase strains are non-viable. To investigate the role of PtdIns(4,5)P # in mediating the phenotype of double and triple 5-phosphatase null mutant yeast, we determined whether a mammalian PtdIns(4,5)P # 5-phosphatase, 5-phosphatase II, which lacks polyphospho-
INTRODUCTION
Phosphatidylinositols play complex signalling roles in both mammalian and yeast cells. The turnover of these ubiquitous minor membrane lipids following extracellular stimuli regulates cell growth and death [1] , vesicular trafficking [2] and actin cytoskeletal rearrangement [3] . Phosphatidylinositol 4,5-bisphosphate [PtdIns (4, 5) P # ] serves as a precursor to both soluble inositol phosphates [4] and phosphorylated phosphatidylinositols [5] , and, via interactions with actin-binding proteins, regulates actin cytoskeletal rearrangement [3] . Cellular levels of PtdIns(4,5)P # are maintained by its synthesis from phosphatidylinositol by specific lipid kinases [6, 7] , hydrolysis by phospholipase C following agonist stimulation [4] , and dephosphorylation by specific lipid phosphatases designated inositol polyphosphate 5-phosphatases (hereafter called 5-phosphatases). This extensive enzyme family regulates PtdIns(4,5)P # concentrations by dephosphorylating the phosphate at the 5-position, forming phosphatidylinositol 4-phosphate (PtdIns4P) [8, 9] . Nine mammalian 5-phosphatases have been characterized, while four isoforms have been identified in the yeast Saccharomyces cere isiae.
Mammalian 5-phosphatases demonstrate distinct substrate specificities, dephosphorylating the 5-position phosphate from both phosphoinositides and inositol phosphates [10] . Recent studies of gene-targeted deletion of various 5-phosphatase Abbreviations used : 5-phosphatase, inositol polyphosphate 5-phosphatase ; GroPtdIns, glycerophosphatidylinositol ; ∆inp51∆inp52∆inp53 5-ptase II, ∆inp51∆inp52∆inp53 triple mutant with 5-phosphatase II expression under control of the GAL1 promoter. 1 To whom correspondence should be sent, at present address : Lymphocyte Signalling and Development Laboratory, Molecular Immunology Programme, The Babraham Institute, Babraham, Cambridge CB2 4AT, U.K. (e-mail cindy.omalley!bbsrc.ac.uk).
inositide phosphatase activity, could correct the phenotype of triple 5-phosphatase null mutant yeast and restore cellular PtdIns(4,5)P # levels to near basal values. Mammalian 5-phosphatase II expressed under an inducible promoter corrected the growth, cell wall, vacuolar and actin polymerization defects of the triple 5-phosphatase null mutant yeast strains. Cellular PtdIns(4,5)P # levels in various 5-phosphatase double null mutant strains demonstrated significant accumulation (4.5-, 3-and 2-fold for ∆inp51∆inp53, ∆inp51∆inp52 and ∆inp52∆inp53 double null mutants respectively), which was corrected significantly following 5-phosphatase II expression. Collectively, these studies demonstrate the functional and cellular consequences of PtdIns(4,5)P # accumulation and the evolutionary conservation of function between mammalian and yeast PtdIns(4,5)P # 5-phosphatases.
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isoforms in mice have demonstrated the significant role that these enzymes play in regulating cellular function. Mice lacking SHIP (SH2-containing inositol phosphatase), which principally hydrolyses PtdIns(3,4,5)P $ and Ins(1,3,4,5)P % and has a restricted expression to haematopoietic cells, demonstrate massive increases in white cells, which infiltrate the spleen and lungs [11] [12] [13] . Although humans with mutations in the Lowe's protein demonstrate Lowe's oculocerebrorenal syndrome, mental retardation, renal failure and cataracts [14] , gene-targeted deletion of this 5-phosphatase in mice results in no phenotype [15] . Similarly, mice lacking 5-phosphatase II are normal, suggesting functional redundancy of these two enzymes. Gene-targeted deletion of 5-phosphatase II together with the Lowe's protein is lethal in utero. Mice lacking the neural synapse 5-phosphatase synaptojanin demonstrate neurological abnormalities and die shortly after birth [16] . Collectively, these studies demonstrate the important role of 5-phosphatase enzymes in regulating apoptosis, synaptic vesicle recycling, cell growth and development. However, as these 5-phosphatases each hydrolyse multiple phosphatidylinositol-derived messenger molecules, the precise mechanisms by which these cellular derangements occur are currently unclear.
Four 5-phosphatases have been identified and partially characterized in the yeast S. cere isiae [17] [18] [19] [20] . Three enzymes, designated Inp51p, Inp52p and Inp53p (also known as Sjl1p, Sjl2p and Sjl3p, for ' synaptojanin like') [21] , contain an N-terminal Sac1-like domain that demonstrates identity with yeast Sac1p, a central catalytic 5-phosphatase domain and C-terminal proline-rich sequences. The Sac1-like domains of mammalian synaptojanin and yeast Inp52p and Inp53p, but not Inp51p, possess intrinsic polyphosphoinositide phosphatase activity that hydrolyses PtdIns3P, PtdIns4P and PtdIns(3,5)P # to PtdIns [22] . A fourth yeast 5-phosphatase, Inp54p, has been identified which contains a 5-phosphatase domain but no other recognized signalling motifs [23] . The 5-phosphatase domain of all the yeast 5-phosphatases hydrolyses PtdIns(4,5)P # , forming PtdIns4P [20] . Single null mutants of ∆inp51, ∆inp52 and ∆inp53 are viable [18] . However, single ∆inp51 mutants display increases in cell growth at low temperatures. The double mutants ∆inp51∆inp52, ∆inp52∆inp53 and ∆inp51∆inp53 demonstrate impaired cell growth [17] , abnormalities in vacuole morphology, plasma membrane invaginations and cell wall thickening [19,19a,21] . Polarity of budding and actin abnormalities, as well as aberrant mitochondrial organization, have also been described [21] . Endocytic defects have been detected in ∆inp51∆inp52 null mutants and, to a lesser degree, ∆inp52∆inp53 double mutants [21] . In addition, Inp53p has been implicated in clathrin-mediated protein sorting at the trans-Golgi network [24] . Deletion of all three Sac1-likedomain-containing yeast 5-phosphatases is lethal.
The relative contribution of each yeast 5-phosphatase in the maintenance of phosphoinositide levels in i o is complicated by the overlapping substrate specificity of each isoform, as all hydrolyse PtdIns(4,5)P # forming PtdIns4P. In addition, the Sac1-like domain of Inp52p and Inp53p expresses polyphosphoinositide phosphatase activity [22] . Analysis of cell lysates for PtdIns(4,5)P # 5-phosphatase activity has revealed, in the single null mutants, a reduction in enzyme activity, which was most marked in the ∆inp53 mutant [19,19a] ; the double null mutants showed decreases in cellular PtdIns(4,5)P # 5-phosphatase activity compared with the wild type (∆sjl1∆sjl2, 64% ; ∆sjl1∆sjl3, 22% ; ∆sjl2∆sjl3, 14%). Analysis of the endogenous lipids by TLC, which does not distinguish between the phosphoinositide isomers PtdIns(4,5)P # and PtdIns(3,5)P # , demonstrated a 2-fold increase in PtdInsP # in the ∆inp51 single mutant and the ∆inp51∆inp52 and ∆inp51∆inp53 double null mutants, but not in the ∆inp52∆inp53 strain [17] . HPLC analysis of specific phosphoinositides has only been reported for the ∆inp52∆inp53 null mutant, and no accumulation of PtdIns(4,5)P # , PtdIns3P or PtdIns4P was detected [22] . Therefore the phenotype, which is observed in all double null 5-phosphatase mutants, does not necessarily correlate with phosphoinositide levels.
In the present study, we demonstrate that the phenotype associated with deletion of the yeast Sac1-like-domain-containing 5-phosphatases correlates with a significant accumulation of PtdIns(4,5)P # , and can be rescued by a mammalian isoform, 5-phosphatase II (also called the 75 kDa 5-phosphatase) [25] . This mammalian PtdIns(4,5)P # 5-phosphatase does not contain a Sac1-like domain, indicating that the regulation of PtdIns(4,5)P # by the 5-phosphatase domain, rather than that of PtdIns, PtdIns3P, PtdIns4P or PtdIns(3,5)P # by the Sac1-like domain, contributes to the phenotype observed in double and triple yeast 5-phosphatase null mutant yeast strains. 
MATERIALS AND METHODS

Materials
Genetic manipulations
The genes for INP51, INP52 and INP53 were disrupted with the URA3, HIS3 and TRP1 genes respectively. Specifically, an " 1.4 kb internal segment of INP51 (472-1949 bp) was PCRamplified from S. cere isiae genomic DNA with added restriction sites (XbaI and HindIII), and cloned into pBluescript. The " 1.3 kb URA3 gene was excised from plasmid pJJ242 by digestion with EcoRI and P uII, and was ligated in place of the 232 bp (nucleotides 1218-1449) EcoRI\EcoRV fragment in the INP51 PCR construct. Diploid S. cere isiae (W303) were transformed by electroporation with the entire cDNA fragment excised from pBluescript (NotI\XhoI), encoding URA3 flanked by INP51. Uraj transformants were screened for homologous insertion of the construct by PCR, using an internal URA3 primer and the 3h-primer of the INP51 construct.
Disruption of the INP52 gene was performed using the HIS3 gene. The HIS3 gene was PCR-amplified from plasmid pRS303, and complementary flanking regions to INP52 and pRS were added to produce a fragment encoding HIS3 flanked by INP52 coding sequences. Homologous recombination between the flanking INP52 regions resulted in the insertion of the HIS3 cassette and replacement of 1747-2721 bp in INP52. This construct was electroporated into diploid S. cere isiae (W303) and Hisj transformants were selected. Homologous insertion of the construct was determined by PCR, as for the ∆inp51 transformants.
The disruption of the INP53 gene was performed in an analogous manner to INP52 disruption. TRP1 was PCR-amplified from plasmid pRS304 with flanking regions from INP53 corresponding to 1868-1912 bp and 2822-2866 bp. Homologous recombination between the flanking INP53 regions resulted in insertion of the TRP1 cassette and replacement of nucleotides 1913-2821 in INP53. This construct was electroporated into diploid S. cere isiae (W303) and Trpj transformants were selected. Homologous insertion of the construct was determined by PCR, as for the ∆inp51 and ∆inp52 transformants.
Following selection of diploid cells containing the relevant construct, diploid cells were induced to sporulate and tetrads were dissected to obtain haploid cells containing the disrupted genes. The single mutants were then mated and sporulated by standard techniques to obtain the haploid double null mutants ∆inp51∆inp52, ∆inp51∆inp53 and ∆inp52∆inp53. To obtain a triple mutant, the ∆inp51 null mutant was mated with the ∆inp52∆inp53 mutant. Diploid cells containing all three mutant genes (∆inp51∆inp52∆inp53) demonstrated normal growth and viability, but the haploid cells were non-viable.
5-Phosphatase II was PCR-amplified from cDNA encoding mouse 5-phosphatase II between nucleotides 108 and 3203. An alternatively spliced CAAX-less variant of 5-phosphatase II was used (GenBank accession number AY007563). The primers used were : 5-prime, ggactagtttgacagctcagcatgga (which encodes nucleotides 108-128 of 5-phosphatase II and a novel SpeI site) ; 3-prime, gggtcgacaattgtggctgccttaa (which encodes nucleotides 3184-3203 plus a novel SalI site). The 3.1 kb PCR product was cloned into the SpeI and SalI sites of the multicloning site of the 
Strains and culture conditions
The S. cere isiae strains used in this study are listed in Table  1 . The ∆inp51∆inp52∆inp53 triple mutant with 5-phosphatase II expression under control of the GAL1 promoter is described as the ∆inp51∆inp52∆inp53 5-ptase II repressed (glucose) or induced (galactose). Cells were cultured in minimal medium lacking the appropriate nutrients to maintain selection conditions for genetic markers. The carbon source utilized was 2 % (w\v) glucose, except when induction of the GAL1 promoter was necessary, in which case galactose was used at 4 % (w\v).
Northern blot
Total RNA was extracted from galactose-induced or glucoserepressed ∆inp51∆inp52∆inp53 5-ptase II S. cere isiae at earlyexponential phase (D '!! " 0.6) by the hot acid\phenol method [27] . A portion of 200 µg of total RNA was denatured and loaded on to a 1 % (w\v) agarose gel containing 0.67 % formaldehyde, and electrophoresed at 80 V for approx. 3 h. The RNA was transferred on to GeneScreen Plus (NEN) for 18 h and fixed by baking at 80 mC for 2 h. The membrane was prehybridized for 2 h in 0.9 M NaCl, 0.05 M Na # PO % , 5 mM EDTA, 5iDenhardt's solution, 50 % formamide and 1 % SDS at 42 mC before addition of the denatured cDNA probe. The 5-phosphatase II cDNA was digested with ApaL1 and DraIII to generate a 797 bp fragment, which was purified (Bresaclean ; Bresatec, Adelaide, Australia) and labelled with [α-$#P]dCTP by random primers using the High Prime kit (Boehringer, Mannheim, Germany). Hybridization of the probe was performed for 18 h at 42 mC, followed by washing twice (10 min each) with 2iSSC (0.3 M NaCl and 0.03 M trisodium citrate)\0.1 % SDS, and then twice with 1iSSC\0.1 % SDS at the same temperature. After autoradiography for between 4 h (see Figure 1 ) and 4 days (to ensure no signal in the glucose-repressed lane), the membrane was allowed to decay for 2 months and then reprobed with an end-labelled oligomer yeast actin probe. A 100 ng portion of the yeast actin oligonucleotide probe (ccataccgaccatgataccttggtgtcttg) was end-labelled with [γ-$#P]-dATP and T4 polynucleotide kinase, and the labelled probe was added to the membrane, which was processed as before. Washing procedures were repeated and autoradiography was performed.
Analysis of growth characteristics in liquid culture
Starter cultures (10 ml) of yeast strains in minimal medium were grown to early exponential phase (D '!! " 0.6) at 28 mC, and then 1 ml was diluted in 100 ml of fresh minimal medium. Cultures were incubated at 28 mC with constant aeration at " 200 rev.\min. Growth was monitored by measuring D '!! every 4 h for up to 36 h, and then every 12 h for up to 5 days. Viability was determined by the exclusion of 0.05 % New Methylene Blue (Malinckrodt). Aliquots of 1 ml were taken daily for fixation, prior to actin and chitin staining.
Electron microscopy
Mid-exponential-phase cultures of S. cere isiae strains were fixed by addition of phosphate-buffered fixative (final concentrations 1 % paraformaldehyde and 1 % glutaraldehyde) for 5 min. After centrifugation (1000 g ; 10 min), the pellet was resuspended in fresh phosphate-buffered 1 % paraformaldehyde\1 % glutaraldehyde for a further 30 min. Following a series of rinses in PBS, cells were resuspended in 1 % aqueous sodium metaperiodate to assist in permeabilizing the cell wall. A second series of rinses in PBS preceded further fixation in 0.5 % aqueous potassium permanganate. Yeast were then washed thoroughly with distilled water, stained en bloc with 2 % aqueous uranyl acetate, and given an extended wash in distilled water. Cells were dehydrated through a graded series of alcohols and embedded in LR White acrylic resin. Ultra-thin sections were prepared on an Ultracut E Ultramicrotome (Leica), stained with methanolic saturated uranyl acetate and Reynolds lead citrate, and viewed in an Hitachi H600 transmission electron microscope.
Staining of actin and chitin
Yeast cells were fixed by the addition of 0.1 ml of formalin (BDH) solution to 0.9 ml aliquots of growth medium for 30 min, followed by resuspension in formalin\PBS [35 
and 4 % formaldehyde for 2 h. The cells were washed once and resuspended in 1 ml of PBS containing 1 % Triton X-100. Actin was stained by addition of 0.3 µM phalloidin\TRITC (tetramethylrhodamine Autoradiography for the 5-phosphatase II probe was performed for 4 h, and extended to 4 days to ensure that no signal developed in the glucose-repressed lane. The membrane was allowed to decay and, to confirm similar loading of RNA in each lane, was re-probed with a 32 P-labelled actin oligonucleotide and autoradiographed for 3 days.
β-isothiocyanate) (Sigma) for 3 h. Excess stain was removed by washing twice in PBSM. Cells were visualized on poly(-lysine)-coated slides using confocal microscopy. Chitin staining was performed by addition of 5 µl of calcofluor (1 mg\ml) to 100 µl of fixed yeast cells for 5 min. Excess stain was removed and cells were resuspended as above. The cells were visualized using a Nikkon Optiphot microscope and a UV-2A filter (excitation 330-380 nm ; barrier filter 420 nm).
Analysis of cellular Ins(1,4,5)P 3 and PtdIns(4,5)P 2 concentrations
Samples for assay were prepared by trichloroacetic acid extraction of yeast cultures grown to early exponential phase (D '!! " 0.6), as described previously [28, 29] . Essentially, 50 ml cultures of yeast were harvested by centrifugation at 1000 g and washed twice in water, prior to resuspension in 2 ml of PBS. Then 1 ml of culture was lysed with an equal volume of ice-cold 1 M trichloroacetic acid and vortex-mixed with glass beads to aid mechanical disruption. This was followed by incubation on ice for 15 min with intermittent vortex mixing. The solid phase was removed by centrifugation at 4000 g for 15 min at 4 mC, and used for extraction of PtdIns(4,5)P # . The supernatant containing the soluble Ins(1,4,5)P $ was extracted three times with 10 ml of water-saturated diethyl ether, and the pH of the supernatant was adjusted to 7.5 with NaHCO $ . The cell pellet was washed with 2 ml of 1 M trichloroacetic acid\1 mM EDTA, followed by distilled water. PtdIns(4,5)P # was extracted from this pellet by addition of 0.94 ml of methanol\chloroform\HCl (80 : 40 : 1, by vol.) for 15 min at room temperature, with intermittent vortex mixing. The lipid and aqueous phases were resolved by the addition of 0.31 ml of chloroform and 0.56 ml of 0.1 M HCl, followed by centrifugation at 1000 g for 15 min. Then 400 µl of the lipid phase was evaporated under nitrogen gas, prior to alkaline hydrolysis of the PtdIns(4,5)P # to Ins(1,4,5)P $ . A 0.25 ml portion of 1 M KOH was added to the dried lipid and heated at 100 mC for 15 min. Excess alkali was removed by filtration through Dowex 50 (200-400 mesh ; H + form). The eluate was washed with 2i2 ml of butan-1-ol\light petroleum ether (5 : [30] . HPLC analysis was performed using a Zorbax SAX column (4.6 mmi250 mm ; 5 µm) with the following protocol and reagents : buffer A, distilled water ; buffer B, 1.25 M (NH % ) # HPO % , pH 3.8 ; pump program : 0 % B at 0 min ; 5 min at 0 % B ; 65 min at 12 % B ; 110 min at 80 % B.
RESULTS
We investigated the role of PtdIns(4,5)P # in mediating the phenotypes observed in double and triple null mutant strains of yeast that lack the Sac1-like-domain-containing 5-phosphatases Inp51p, Inp52p and Inp53p (Figure 1a) . We compared the phenotypes of the single, double and triple yeast 5-phosphatase null mutants, in which the 5-phosphatase domain was disrupted, with that of a triple null mutant strain rescued by the mammalian 5-phosphatase II. The latter 5-phosphatase does not express polyphosphoinositide phosphatase activity, and the principal substrate of this mammalian homologue is PtdIns(4,5)P # . The substrates of 5-phosphatase II include PtdIns(4,5)P # , PtdIns(3,4,5)P $ , Ins(1,4,5)P $ and Ins(1,3,4,5)P % . However, yeast do not synthesize PtdIns(3,4,5)P $ , while Ins(1,4,5)P $ and Ins(1,3,4,5)P % do not constitute major signalling pathways in yeast, compared with mammalian cells [31, 32] .
As shown by previous studies, the yeast triple null mutant ∆inp51∆inp52∆inp53 resulted in a lethal phenotype, as determined by tetrad analysis (results not shown). We transformed this triple null mutant strain with a cDNA encoding a mouse 5-phosphatase II (nucleotides 108-3203) under the control of the GAL1 promoter (∆inp51∆inp52∆inp53 5-ptase II). This cDNA encodes a spliced isoform of murine 5-phosphatase II which does not encode a C-terminal CAAX motif, but does encompass the entire 5-phosphatase domain and therefore should localize predominantly to the cytosolic fraction. The expression of the mammalian 5-phosphatase II following induction with galactose was demonstrated by Northern analysis (Figure 1b) . In the presence of glucose (2 %, w\v), expression was suppressed and no 5-phosphatase II transcript was observed. In contrast, following induction with galactose (4 %, w\v), a 3.1 kb transcript was detected in yeast lysates, consistent with the predicted size of the 5-phosphatase II transcript. In addition, immunoblot analysis using mammalian 5-phosphatase II anti-peptide antibodies demonstrated the expression of a 93 kDa polypeptide in galactose-induced yeast cell lysates that was not detected in glucose-treated cells (results not shown). Attempts to determine the intracellular location of murine 5-phosphatase II expressed in yeast using affinity-purified antibodies to this isoform were unsuccessful due to significant non-specific staining.
Growth characteristics of 5-phosphatase null mutant yeast
To determine if 5-phosphatase II was functional in yeast and could rescue the lethal triple null mutant 5-phosphatase phenotype, we analysed the growth characteristics of the wild type, a representative double mutant ∆inp51∆inp52, and the ∆inp51∆inp52∆inp53 5-ptase II strain, both induced (galactose), or repressed (glucose) (Figure 2a) . The double ∆inp51∆inp52 mutant grew at a similar initial rate to wild-type yeast, but did not reach as high an attenuance at saturation. The ∆inp51∆inp52∆inp53 5-ptase II strain cultured in the presence of glucose demonstrated no growth. In contrast, when cultured in the presence of galactose, the ∆inp51∆inp52∆inp53 5-ptase II strain demonstrated a prolonged lag phase of approx. 20 h, before rapid exponential growth was achieved ; saturation was reached at an attenuance comparable with that of the wild type. Consistent with this analysis, the ∆inp51∆inp52∆inp53 5-ptase II strain was inviable when cultured in glucose : within 4 days, 80 % of the cells had died (Figure 2b ). In contrast, following induction with galactose, the viability of the ∆inp51∆inp52∆inp53 5-ptase II strain was similar to that of the wild type, and showed enhanced survival compared with ∆inp51∆inp52. These results suggest the 5-phosphatase domain from a mammalian enzyme, in the absence of a Sac1-like domain, can function in yeast to rescue the lethal 5-phosphatase triple null mutant phenotype.
Phenotypes of 5-phosphatase null mutant strains
We undertook ultrastructural studies using electron microscopy to compare the phenotypes of 5-phosphatase null mutant strains with those rescued by mammalian 5-phosphatase II (Figures  3a-3f ). Wild-type S. cere isiae contain a single nucleus, with usually a single large vacuole or occasionally several smaller vacuoles, a regular plasma membrane and constant cell wall thickness. As reported previously, ∆inp51∆inp52 double mutants demonstrate grossly abnormal morphology, characterized by a markedly thickened cell wall, fragmentation of vacuoles and an irregular plasma membrane with massive invaginations (Figures  3c and 3d) [17,19,19a,21] . The ∆inp51∆inp52∆inp53 5-ptase II strain induced with galactose demonstrated a variable phenotype, with many cells showing a near wild-type morphology ( Figure  3f ) . However, several cells demonstrated structural changes comparable with those in the double null mutant strain, with a grossly thickened cell wall (Figure 3e ). The cDNA encoding 5-phosphatase II was cloned into a centromeric plasmid that limits plasmid numbers to a single copy in each cell. Induction of the GAL1 promoter will lead to high levels of 5-phosphatase II expression, but there may be some cellular variation in expression of this enzyme. It was noteworthy that most cells expressing 5-phosphatase II in the triple null mutant strain demonstrated a significantly improved morphology compared with the ∆inp51∆inp52 double mutant. In general, the cell wall was thinner, vacuoles were larger and less numerous, and the plasma membrane invaginations were less apparent in the majority of cells.
Correction of actin polarization and budding polarity defects by mammalian 5-phosphatase II expression
Defects in actin organization and bud polarity in 5-phosphatase double null mutants have been described in several studies [19,19a,21] . In normal vegetative yeast, actin is localized to patches that are distributed randomly throughout the cortex. The double mutant ∆inp51∆inp52 showed heterogeneous patch size and large accumulations of actin (Figure 4c ). The repressed ∆inp51∆inp52∆inp53 5-ptase II was grossly abnormal, with very large accumulations of cortical actin (Figure 4g ). In contrast, the induced ∆inp51∆inp52∆inp53 5-ptase II revealed a normal distribution of actin, similar to that in wild-type yeast (Figure 4e ).
Actin distribution within budding yeast cells depends on the
Figure 3 The ultrastructure of triple null mutant yeast is grossly abnormal, and can be rescued by the expression of murine 5-phosphatase II
Electron micrographs of yeast strains were prepared as described in the Materials and methods section. Scale bars represent 1 µm. Panels (a) and (b) illustrate wild-type yeast, panels (c) and (d) show representative examples of the grossly abnormal appearance of ∆inp51∆inp52, and panels (e) and (f ) demonstrate the heterogeneity of the ultrastructural morphology of the ∆inp51∆inp52∆inp53 5-ptase II induced strain. The majority of cells appeared as shown in (f ).
stage of the cell cycle. Early in the budding process, actin patches predominate in the bud, and actin cables within the mother cell are oriented towards the bud. As the bud size increases, actin localizes within both cells, until, at cytokinesis, the actin patches distribute around the bud neck. The ∆inp51∆inp52 double mutant demonstrated an aberrant distribution of actin, which was present both in the mother cell and in the bud in large patches ( Figure  4d ). The number of budding cells within the repressed ∆inp51∆inp52∆inp53 5-ptase II was minimal ; however, a grossly aberrant actin distribution was apparent (Figure 4h ). In contrast, the induced ∆inp51∆inp52∆inp53 5-ptase II showed a completely normal actin distribution in most budding cells, with correction of the actin polarity defects. Occasional budding yeast demonstrated mild aberrations in actin morphology, but these were rare.
Calcofluor stains chitin, a cell wall component that is present in ' bud-scars '. In normal haploid cells, new bud-sites are selected at a site adjacent to previous bud-sites, and chitin rings mark the sites where scission occurred. The ∆inp51∆inp52 mutant showed much brighter staining than the wild type, and the process of Murine 5-phosphatase II rescue of lethal yeast 5-phosphatase knockout bud-site selection appeared random (Figure 5b ). The repressed ∆inp51∆inp52∆inp53 5-ptase II mutant demonstrated grossly abnormal bud-site selection, with massive overproduction of chitin (Figure 5d ). The induced ∆inp51∆inp52∆inp53 5-ptase II strain (Figure 5c ) showed increased staining, but to a much lesser extent than either the ∆inp51∆inp52 or repressed ∆inp51∆inp52∆inp53 5-ptase II strains.
Collectively, these studies demonstrate that expression of mammalian 5-phosphatase II, a PtdIns(4,5)P # 5-phosphatase, can correct the defects in cell growth, actin polymerization, cell wall thickness, vacuole fragmentation and bud-site selection observed in yeast 5-phosphatase null mutant strains.
Phosphoinositide levels in 5-phosphatase null mutant yeast
Several studies have reported the phenotype of the 5-phosphatase null mutants and determined phosphoinositide levels using a variety of techniques. Stolz et al. [18] , using TLC, analysed the levels of phosphoinositides in various mutants ; however, this analysis does not separate PtdIns(4,5)P # from PtdIns(3,5)P # . In that study [18] , PtdInsP # levels were elevated in the ∆inp51, ∆inp51∆inp52 and ∆inp51∆inp53 mutants by only 2-fold ; surprisingly, although the ∆inp52∆inp53 mutant demonstrates a similar phenotype, no abnormalities in phosphoinositide levels were detected. Further analysis of the ∆inp52∆inp53 strain using [$H]inositol labelling of yeast and analysis of deacylated lipids by HPLC confirmed there was no accumulation of PtdIns(4,5)P # [22] . Comparable HPLC analysis of other double mutants has not been reported.
We undertook a detailed analysis of PtdIns(4,5)P # levels in 5-phosphatase null mutant yeast and triple 5-phosphatase null mutant yeast rescued by 5-phosphatase II using three distinct strategies. First, we measured PtdIns(4,5)P # concentrations using a radioreceptor Ins(1,4,5)P $ binding assay, as described previously [28, 29] . This assay does not rely on equilibrium labelling of yeast. Secondly, we measured phosphoinositides in [$H]-inositol-labelled yeast grown to mid-exponential phase (five doublings). Finally, yeast were labelled for a more extended period of 72 h to stationary phase. Recent studies have shown that the growth status of the cells when they are harvested may modify the responses of phosphoinositides. For example, PtdIns(3,5)P # levels are only induced in exponentially growing cells that are subjected to hyperosmotic stress [30] . In addition, several studies have suggested that phosphoinositides may be compartmentalized into several distinct compartments -agonistsensitive and -insensitive [33] . Heterogeneous pools of PtdIns(4,5)P # exist within the plasma membrane of cells. In mammalian cells, PtdIns(4,5)P # has been shown to associate with other signalling molecules within membrane microdomains formed by lateral association of sphingolipids and cholesterol [34] . Lipid rafts have also been demonstrated in yeast [35, 36] . These microdomains are thought to contain the agonist-sensitive pools of PtdIns(4,5)P # that correlate directly with the metabolically labelled pools [33, 37] . We reasoned that labelling of exponentially growing yeast may only result in incorporation of [$H]inositol into the rapidly turning over agonist-sensitive phosphoinositide pool, and that more prolonged labelling may be required for incorporation of [$H]inositol into other phosphoinositide compartments.
Total cellular PtdIns(4,5)P # and Ins(1,4,5)P $ concentrations were measured using the Ins(1,4,5)P $ radioreceptor assay. Endogenous Ins(1,4,5)P $ and PtdIns(4,5)P # were extracted from yeast and the PtdIns(4,5)P # was converted into Ins(1,4,5)P $ by alkaline hydrolysis. The concentration of endogenous PtdIns(4,5)P # in wild-type yeast was 147 pmol\mg, which was increased to 730 pmol\mg (5-fold increase) in the ∆inp51∆inp52 mutant (Table 2 ). In contrast, the galactose-induced ∆inp51∆inp52∆inp53 5-ptase II strain demonstrated a significant decrease (2-fold) in PtdIns(4,5)P # levels compared with the double null mutant. As the triple knockout is likely to have a greatly elevated endogenous PtdIns(4,5)P # level compared with the double mutant, the reduction in PtdIns(4,5)P # in the 5-phosphatase rescued triple mutant strain may be even more significant. In contrast, the levels of Ins(1,4,5)P $ did not appear to differ significantly in the three yeast strains tested (Table 2) .
We analysed phosphoinositides in wild-type and 5-phosphatase null mutant yeast by labelling with [$H]inositol for five population doublings, to ensure that 95 % of the total yeast mass was derived from substrates, including radiolabelled inositol, in the growth medium. The lipids were extracted, deacylated to glycerophosphoinositols (GroPtdIns) and analysed by HPLC. The identity of the elution peak was confirmed by comparison with the elution profiles of known standards [GroPtdIns4P, GroPtdIns(4,5)P # and GroPtdIns(3,5)P # ], and each peak was standardized to the GroPtdIns peak height. PtdIns(4,5)P # levels were increased by 1.3-fold in the ∆inp51∆inp52 mutant, but this was not statistically significant (Table 3 ; Figure 6 ). The only previous study analysing PtdIns (4, 5) P # levels in this strain demonstrated a 2-fold increase in this phosphoinositide ; however, TLC analysis rather than HPLC analysis of the deacylated lipid products was used to separate the phosphoinositides, and therefore would not have discriminated between PtdIns(3,5)P # and PtdIns(4,5)P # . In contrast, the ∆inp51∆inp52∆inp53 5-ptase II
Figure 6 Phosphoinositide levels in wild-type and 5-phosphatase mutant strains following labelling with myo-[
H]inositol for five population doublings
Yeast strains were labelled with myo-[ 3 H]inositol, as described in the Materials and methods section, for five population doublings (8-24 h). Lipids were extracted and deacylated for analysis by HPLC. GroPtdIns species were identified by comparison with the elution profile of known standards. The mean peak height (c.p.m.) standardized to GroPtdIns is reported in Table  3 as the percentage (meanpS.D.) for three independent assays. Representative HPLC profiles are illustrated for the wild-type (a), ∆inp51∆inp52 (b) and ∆inp51∆inp52∆inp53 5-ptase II induced (c) strains.
induced strain demonstrated a significant decrease in all phosphoinositides compared with the wild type [29 % for GroPtdIns3P, 56 % for GroPtdIns4P and 25 % for GroPtdIns(4,5)P # ]. Inaccuracies due to varying growth rates were minimized by culturing for a defined number of population doublings. We undertook standardization of peak heights to that of GroPtdIns to minimize variations in labelling or in extraction of phosphoinositides. It is noteworthy that the mean peak of GroPtdIns for the wild type was of a similar order to that obtained for the ∆inp51∆inp52∆inp53 5-ptase II induced strain (1 836 438 and
Figure 7 PtdIns(4,5)P 2 levels are elevated in all double mutant 5-phosphatase null strains
Yeast strains were labelled with myo- [ 3 H]inositol, as described in the Materials and methods section, for 72 h. Lipids were extracted and deacylated for analysis by HPLC. GroPtdIns species were identified by comparison with the elution profile of known standards. Mean peak height (c.p.m.) standardized to GroPtdIns is reported as the percentage (meanpS.D. for three independent assays. Endogenous GroPtdIns(4,5)P 2 (a), GroPtdIns3P (b) and GroPtdIns4P (c) for (from left to right) the wild-type, ∆inp51∆inp52, ∆inp51∆inp53, ∆inp52∆inp53 and ∆inp51∆inp52∆inp53 5-ptase II induced strains are illustrated. Representative HPLC elution profiles are shown for the wild-type (d), ∆inp51∆inp52 (e), ∆inp51∆inp53 (f ), ∆inp52∆inp53 (g) and ∆inp51∆inp52∆inp53 5-ptase II induced (h) strains.
2 638 589 c.p.m. respectively), suggesting that extraction rates were similar and labelling comparable. In addition, the mass assay used to quantify PtdIns(4,5)P # levels in this mutant strain did not demonstrate a decrease in PtdIns(4,5)P # levels below those in the wild type (see Table 2 ). Collectively, these results suggest that the significant decrease in the levels of phosphoinositides, and in particular of PtdIns(4,5)P # , in the ∆inp51∆inp52∆inp53 5-ptase II induced strain does not result from reduced levels of endogenous lipids, but is more likely to reflect decreased or delayed synthesis of these phosphoinositides in the agonist-sensitive pool. There were no significant differences noted between the levels of GroPtdIns3P or GroPtdIns4P in the wild type compared with the ∆inp51∆inp52 double mutant (Table  3 ; Figure 6 ).
To investigate PtdIns(4,5)P # levels in 5-phosphatase null mutants further, we increased the time of [$H]inositol labelling in all strains to 72 h (as compared with 8-24 h for five population doublings, dependent on the yeast strain) to ensure saturation labelling ( Figure 7 ). All 5-phosphatase double mutants demonstrated a significant accumulation of GroPtdIns(4,5)P # , which was most marked (4-fold) in the ∆inp51∆inp53 double mutant. There was a 3-fold increase in the ∆inp51∆inp52 strain, but a 2-fold increase was also observed in the ∆inp52∆inp53 double null mutant, which has not been noted in previous studies [22] . This analysis suggests that the accumulation of PtdIns(4,5)P # may be related to the growth phase of the yeast.
Furthermore, GroPtdIns(4,5)P # levels in the galactose-induced ∆inp51∆inp52∆inp53 5-ptase II strain were 2-fold above those in the wild type, and this showed a significant correction compared with the ∆inp51∆inp53 double null mutant. It is of interest that, although PtdIns(4,5)P # levels were significantly reduced in triple null mutant strains overexpressing 5-phosphatase II to levels observed in the ∆inp52∆inp53 double null mutant, the phenotype observed in the latter strain (in particular defects in actin polymerization) was more severe (results not shown). These results suggest that it is not the absolute level of PtdIns(4,5)P # that is correlated directly with the severity of the phenotype. Localized increases in phosphoinositides in specific membrane compartments may contribute significantly to the observed phenotype.
As the Sac1-like domains of Inp52p and Inp53p hydrolyse PtdIns4P and PtdIns3P, forming PtdIns, we investigated the levels of PtdIns3P and PtdIns4P in 5-phosphatase null mutant yeast. Increases of 1.2-and 1.5-fold in GroPtdIns4P levels were consistently observed in the ∆inp51∆inp52 and ∆inp51∆inp53 null mutant yeast, but no change was noted in the ∆inp52∆inp53 strain. GroPtdIns3P levels were elevated 2.5-fold in ∆inp51∆inp53 null mutants, but not in any other 5-phosphatase null mutant strains. It was noteworthy that this accumulation of PtdIns3P and PtdIns4P was not significantly corrected by 5-phosphatase II expression.
DISCUSSION
The study reported here demonstrates that overexpression of a mammalian 5-phosphatase can rescue the lethal phenotype of a triple null mutant yeast 5-phosphatase strain. Overexpression of 5-phosphatase II, a mammalian PtdIns(4,5)P # 5-phosphatase, corrected defects in actin polymerization and bud-site selection, and partially rescued massive cell wall thickening and fragmented vacuole morphology. We have demonstrated that all yeast 5-phosphatase double null mutant strains are characterized by a significant increase in cellular PtdIns(4,5)P # levels. As a result of this analysis, we can assign some of the phenotypic features, in particular defects in actin polymerization, bud-site selection and fragmented vacuole morphology, observed in the 5-phosphatase null mutant strains to increases in PtdIns(4,5)P # levels, as this was the only phosphoinositide that demonstrated significant accumulation. However, the absolute cellular level of PtdIns(4,5) P # does not correlate directly with specific phenotypes. In our study, the disruption of INP52 and INP53 was designed to occur after the Sac1-like domain ( Figure 1a) ; however, we cannot exclude the possibility that such a truncated protein is unstable, and that the Sac1-like domains of Inp52p and Inp53p are non-functional. It is noteworthy that the phenotype of the 5-phosphatase null mutants that we report is the same as has been described in three previous studies, despite differences in the design of the null mutants. In each study, including ours, the triple null mutant is lethal, while the various 5-phosphatase double null mutants are characterized by a thickened cell wall, vacuole fragmentation, actin polymerization and bud-site selection defects, and abnormalities in endocytosis. In two previously reported studies, the entire open reading frame of each 5-phosphatase was replaced [17, 21] . However, in the original study by Srinivasan et al. [19] , given the design of the constructs, the possibility cannot be excluded that the Sac1-like domain of Inp51p and Inp52p was functional. The Sac1-like domain of Inp52p and Inp53p hydrolyses PtdIns3P, PtdIns4P and PtdIns(3,5)P # ; however, no definitive HPLC analysis of the endogenous levels of these phosphoinositides in either the single or double 5-phosphatase null mutants has been reported, except for the ∆inp52∆inp53 strain [22] . In this latter report, no differences in the levels of PtdIns3P or PtdIns4P were detected after 10 population doublings, although at early exponential phase the levels of PtdIns(3,5)P # were increased 5-7-fold after stress. We also demonstrated no changes in the levels of PtdIns3P and PtdIns4P in the ∆inp52∆inp53 null mutant strain ; under our prolonged labelling conditions and in the absence of osmotic shock, we would not anticipate detecting changes in PtdIns(3,5) P # . However, we noted, following prolonged labelling of yeast for 72 h, a significant increase in the levels of PtdIns3P, and to a lesser extent PtdIns4P, in the ∆inp51∆inp52 null mutant strain, suggesting that the Sac1-like domain of Inp52p is non-functional and that accumulation of these phosphoinositides may be detected given prolonged labelling conditions. Consistent with this contention, induction of 5-phosphatase II, which does not contain a Sac1-like domain, did not correct the level of these phosphoinositides, but reduced the accumulation of PtdIns(4,5) P # and corrected the abnormal phenotype.
Decreased labelling of phosphoinositides in 5-phosphatase null mutant strains
We have demonstrated that the levels of PtdIns(4,5)P # detected in 5-phosphatase null mutant strains are variable and dependent on the time period of [$H]inositol labelling. We have shown, using more prolonged labelling, significant increases in the levels of PtdIns(4,5)P # of 4.5-, 3-and 2-fold in the ∆inp51∆inp53, ∆inp51∆inp52 and ∆inp52∆inp53 double null mutants respectively. Previous studies have suggested that either Inp53p [19,19a] or Inp51p [17] is the most active PtdIns(4,5)P # 5-phosphatase in yeast. In our study, it was noteworthy that the highest levels of endogenous PtdIns(4,5)P # were detected in strains in which INP51 was disrupted, suggesting that this enzyme is the most active of the yeast 5-phosphatases in regulating PtdIns(4,5) P # levels, consistent with the report by Stolz et al. [18] . Although all yeast 5-phosphatases have been shown to hydrolyse PtdIns(4,5)P # , the relative affinity of each isoform for this phosphoinositide has yet to be determined. Also, PtdIns(4,5)P # has a proposed signalling function in many membrane compartments, including the inner wall of the plasma membrane, Golgi membranes and the endoplasmic reticulum. The localized regulation of this phosphoinositide in these sites by specific 5-phosphatases is therefore of central importance.
The HPLC analysis of endogenous phospholipids was initially performed on yeast strains in exponential growth labelled for five population doublings. No accumulation of PtdIns(4,5)P # was detected in the ∆inp51∆inp52 strain or the ∆inp51∆inp52inp53 5-ptase II induced triple null mutant strain. This was not due to inadequate labelling, as cell counts were used to standardize this parameter, nor was it due to inadequate extraction procedures, as the peak height of [$H]GroPtdIns was of the same order as in the wild type. In contrast, the ∆inp51∆inp52 strain labelled for 72 h demonstrated a 4-fold accumulation of PtdIns(4,5)P # and a 5-fold increase in PtdIns(4,5)P # using specific mass assays. The analysis of PtdIns(4,5)P # levels after labelling for five population doublings was performed at a very early exponential phase of growth. In contrast, the radioreceptor PtdIns(4,5)P # mass assays were performed at an early to mid exponential phase of growth, and the 72 h labelling of [$H]inositols in yeast was performed when the cell culture had achieved saturation. The relative comparison between yeast 5-phosphatase mutant strains demonstrates that there is no significant accumulation of PtdIns(4,5) P # in the early exponential phase of growth (after five population doublings), but that accumulation of PtdIns(4,5)P # becomes apparent at mid-exponential phase [radioreceptor PtdIns(4,5)P # mass assay] and persists until early saturation phase (72 h [$H]inositol labelling). These results suggest that the action of 5-phosphatases in controlling levels of PtdIns(4,5)P # is growthphase-dependent.
5-Phosphatase regulation of PtdIns(4,5) P 2 levels in the cell
The importance of 5-phosphatase isoforms in the regulation of PtdIns(4,5)P # levels in mammalian cells has been demonstrated in several studies. It is noteworthy that cell lines deficient in OCRL (the enzyme deficient in oculocerebrorenal syndrome of Lowe) show a 2-fold accumulation of PtdIns(4,5)P # , as detected by labelling with [$H]inositol for 3 days in culture, until the cells reach confluence [38] . In addition, synaptojanin-1 knockout mice demonstrate a 2-fold accumulation of PtdIns(4,5)P # , but, despite the loss of the Sac1-like domain, show no accumulation of PtdIns3P, PtdIns4P or PtdIns(3,5)P # [16] . Maintenance of PtdIns(4,5)P # levels has been demonstrated to be critical during the yeast cell cycle. Electroporation of a monoclonal antibody directed against PtdIns(4,5)P # into yeast resulted in inhibition of cell growth [39] . The effects of PtdIns(4,5)P # on the actin cytoskeleton of eukaryotic cells have been shown to be many and varied, but, in general, lead to strengthening of the actin network via regulation of various actin-binding proteins, such as profilin, gelsolin and CapZ [40, 41] . The ∆inp51∆inp52 double mutant demonstrated an abnormal actin distribution both in vegetative cells, in which the actin patches were larger than in the wild type, and also in budding cells, which showed delocalization of actin patches to the mother cell. The aberrant actin distribution was grossly exaggerated in the ∆inp51∆inp52∆inp53 5-ptase II suppressed strain, but this defect was completely corrected by 5-phosphatase II expression, correlating with a decrease in PtdIns(4,5)P # levels. The results of this analysis suggest either that the Sac1-like domain plays no role in mediating the phenotype, or that loss of function of the Sac1-like domain may be compensated by significant increases in PtdIns(4,5)P # 5-phosphatase activity.
It is somewhat surprising that the ∆inp52∆inp53 null mutant never demonstrated greater than 2-fold accumulation of cellular PtdIns(4,5)P # , whereas the phenotype of this mutant reveals the most profound defects in actin polymerization. In addition, although the ∆inp51∆inp53 mutant showed the greatest accumulation of PtdIns(4,5)P # (4-fold), the phenotype of this double mutant is less profound than for the other double null mutants ; in particular, actin cytoskeletal abnormalities are not detected, the plasma membrane is only slightly distorted and the vacuolar defects are less apparent [31] . Therefore the cellular accumulation of PtdIns(4,5)P # does not correlate directly with the severity of the phenotype, or with specific phenotypes, although overexpression of a mammalian PtdIns(4,5)P # 5-phosphatase does correct the phenotype. This apparent discrepancy may relate to the specific intracellular location of each 5-phosphatase isoform in yeast. Loss of the localized hydrolysis of PtdIns(4,5)P # in distinct subcellular compartments may contribute to the observed phenotype. Alternatively, the 5-phosphatases, via their respective proline-rich domains, form complexes with specific localized signalling networks, as has been shown for mammalian homologue synaptojanin [42] [43] [44] . As we have expressed mammalian 5-phosphatase II at high levels, and we predict that this would occur predominantly in the cytosol, the regulation of PtdIns(4,5)P # may be corrected in many cellular compartments. The vacuole in yeast is a dynamic organelle that changes its physical characteristics in response to environmental and nutrient stresses [45] , and also during cell division [46] . Changes in vacuolar morphology occur by progressive cycles of fragmentation and fusion of vacuoles, which has been classified into four stages : priming, tethering, docking and fusion [47] . The abnormal vacuole morphology illustrated here for the ∆inp51∆inp52 double mutant demonstrates multiple small vacuoles, suggesting that fusion is inhibited in this strain. Synthesis of PtdIns4P and PtdIns(4,5)P # , but not PtdIns3P or PtdIns(3,5)P # , has been demonstrated to be crucial in this process [48] . It is noteworthy that the ∆inp51∆inp52∆inp53 5-ptase II induced mutant strain demonstrated a marked improvement in vacuolar morphology compared with the double null mutant strains. We propose that the improvements in actin organization, chitin deposition and vacuolar morphology in the ∆inp51∆inp52∆inp53 5-ptase II induced mutant strain are correlated with the improvement in the cellular levels of PtdIns(4,5)P # , rather than of other phosphoinositides such as PtdIns3P, PtdIns4P and PtdIns(3,5)P # regulated by the Sac1-like domain.
Finally, recent studies in our laboratory and others have shown that the catalytic mechanism of action of 5-phosphatases is highly conserved between yeast and mammalian isoforms, and resembles that of the apurinic\apyrimidine endonucleases [49, 50] . Collectively, the studies reported here indicate evolutionary conservation of function between mammalian and yeast 5-phosphatases, and indicate the cellular consequences of PtdIns(4,5)P # accumulation.
